Drugs / LPM3480392
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05857449 | Nov 2021 → Mar 2022 | — | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05862974 | Feb → Nov 2021 | — | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06467409 | Jan 2024 → Jan 2025 | neuropathy, painful | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06204120 | Nov 2022 → Jul 2023 | neuropathy, painful | Luye Pharma Group Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPM3480392 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05862974 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05857449 ↗ |